Answer: Monitoring postmarketing study commitments.
The FDA lacks an effective system for monitoring postmarketing study commitments. See the latest OIG Report, dated June 2006.
Medicare Fraud News, Breaking Headlines and Insight from the Qui Tam Perspective
Answer: Monitoring postmarketing study commitments.
The FDA lacks an effective system for monitoring postmarketing study commitments. See the latest OIG Report, dated June 2006.